The purpose of this research is to assess the mean change in A1C associated with patients who declined a pharmacy-led diabetes management program and to evaluate effects of predictor variables on the odds of achieving improved A1C in these patients.
Patients 18 years or older with uncontrolled type 2 diabetes (defined as A1C ≥ 9%) who declined pharmacy-led diabetes management services were included in the study. The primary outcome of the study was to assess the mean change in A1C from time of phone call offering pharmacy management services (initial) to last observed A1C (final recorded A1C).
Results:
A total of 91 patients were included, 46 males and 45 females. The significant reduction in the mean change from baseline A1C to the final measured A1C was −0.59 (95% CI, −0.9327% to −0.2447%, P-value = 0.0010). This resulted in 8.79% of patients’ final A1C falling into the range of < 7%.
Conclusion:
Our study found a paradoxical reduction in A1C among patients who declined pharmacy-led diabetes management services, however, our study is limited by having no comparison group. Further research needs to be conducted to identify correlations between characteristics of patients declining diabetes management services in order to assist with identifying patient-specific methods for improving patient outcomes.
AliMKBullardKMImperatoreG, et al.Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes—National Health and Nutrition Examination Survey, United States, 2007-2010. MMWR Supplements. 2012;61(2):32–37.
4.
American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S34–S45. doi:10.2337/dc19-S004.
5.
PousinhoSMorgadoMFalcãoA, et al.Pharmacist interventions in the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials. J Manag Care Spec Pharm. 2016;22(5):493–515. doi:10.18553/jmcp.2016.22.5.493
6.
EdwardsHDWebbRDScheidDC, et al.A pharmacist visit improves diabetes standards in a patient-centered medical home (PCMH). Am J Med Qual. 2012;27(6):529–534. doi:10.1177/1062860612444304
7.
ChungNRascatiKLopezD, et al.Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population. J Manag Care Spec Pharm. 2014;20(9):914–919. doi:10.18553/jmcp.2014.20.9.914.
8.
BenedictAWSpenceMMSieJL, et al.Evaluation of a pharmacist-managed diabetes program in a primary care setting within an integrated health care system. J Manag Care Spec Pharm. 2018;24(2):114–122. doi:10.18553/jmcp.2018.24.2.114.
9.
PolonskyWHHenryRR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;22(10):1299–1307. doi:10.2147/PPA.S106821.
10.
CrammJMNieboerAP. Disease management: the need for a focus on broader self-management abilities and quality of life. Popul Health Manag. 2015;18(4):246–255. doi:10.1089/pop.2014.0120.
11.
KatonWJLinEHVon KorffM, et al.Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363(27):2611–2620. doi:10.1056/NEJMoa1003955.
12.
LisiDM. Applying recent A1C recommendations in clinical practice. US Pharm. 2018;43(10):15–22. doi:10.1007/s11892-016-0792-9.
13.
LittleRRRohlfingCL. The long and winding road to optimal HbA1c measurement. Clin Chim Acta. 2013;418:63–71. doi:10.1016/j.cca.2012.12.026
14.
American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Suppl 1):S13–61. doi:10.2337/dc09-S013
15.
JacobsMSherryPSTaylorLM, et al.Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study. J Am Pharm Assoc (2003). 2012 ;52(5):613–621. doi:10.1331/JAPhA.2012.10183
16.
AguiarPMda SilvaCHChiannC, et al.Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: results from a randomized controlled trial. J Eval Clin Pract. 2018;24(1):22–30. doi:10.1111/jep.12606
17.
American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019; 42(Supplement 1):S61–70. doi:10.2337/dc19-S006
18.
IpEJShahBMYuJ, et al.Enhancing diabetes care by adding a pharmacist to the primary care team. Am J Health Syst Pharm. 2013;70(10):877–886. doi:10.2146/ajhp120238
19.
PetersonJHindsAGarzaA, et al.Impact of physician–pharmacist covisits at a primary care clinic in patients with uncontrolled diabetes. J Pharm Pract. 2018;33(3):321–325. doi:10.1177/0897190018807374
20.
McAdam-MarxCDahalAJenningsB, et al.The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes. J Manag Care Spec Pharm. 2015;21(6):452–468. doi:10.18553/jmcp.2015.21.6.452
21.
GarveyWTMechanickJIBrettEM, et al.American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203. doi:10.4158/EP161365.GL
HughesJDWibowoYSunderlandB, et al.The role of the pharmacist in the management of type 2 diabetes: current insights and future directions. Integr Pharm Res Pract. 2017;6:15–27. doi:10.2147/IPRP.S103783
24.
KarrSJackowskiRMBuckleyKD, et al.Cardiovascular risk factors and provision of lifestyle counseling for diabetes or prediabetes with comorbid obesity: analysis of office-based physician visits made by patients 20 years of age or older. Diabetes Spectr. 2019;32(1):53–59. doi:10.2337/ds18-0008
25.
Landa-AnellMVMelgarejo-HernándezMAGarcía-UlloaAC, et al.Barriers to adherence to a nutritional plan and strategies to overcome them in patients with type 2 diabetes mellitus; results after two years of follow-up. Endocrinol Diabetes Nutr. 2020;67(1):4–12. English, Spanish. doi:10.1016/j.endinu.2019.05.007
26.
LawsRAVitaPVenugopalK, et al.Factors influencing participant enrolment in a diabetes prevention program in general practice: lessons from the Sydney diabetes prevention program. BMC Public Health. 2012;12:822. doi:10.1186/1471-2458-12-822
StultsBJonesRE. Management of hypertension in diabetes. Diabetes Spectrum, American Diabetes Association. 2006;19(1):25–31. doi:10.2337/diaspect.19.1.25
29.
FreiAHerzogSWoitzekK, et al.Characteristics of poorly controlled type 2 diabetes patients in Swiss primary care. Cardiovasc Diabetol. 2012;11:70. doi:10.1186/1475-2840-11-70.
30.
ArnettDKBlumenthalRSAlbertMA, et al.2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140(11):e596–e646. doi:10.1161/CIR.0000000000000678.
31.
GrundySMStoneNJBaileyAL, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625.
32.
MaddiganSLFeenyDHJohnsonJA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res. 2005;14(5):1311–1320. doi:10.1007/s11136-004-6640-4.
33.
AdriaanseMCDrewesHWvan der HeideI, et al.The impact of comorbid chronic conditions on quality of life in type 2 diabetes patients. Qual Life Res. 2016;25(1):175–182. doi:10.1007/s11136-015-1061-0.
34.
KhaliliMSabouhiFAbazariP, et al.Comparing the quality of life in insulin recipient and refusal patients with type 2 diabetes. Iran J Nurs Midwifery Res. 2016;21(4):351–356. doi:10.4103/1735-9066.185571.
35.
ØstbyeTYarnallKSKrauseKM, et al.Is there time for management of patients with chronic diseases in primary care?Ann Fam Med. 2005;3(3):209–214. doi:10.1370/afm.310.
